Cargando…

Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”

Detalles Bibliográficos
Autores principales:	Hirata, Takumi, Tomita, Kengo, Kawai, Toshihide, Yokoyama, Hirokazu, Shimada, Akira, Kikuchi, Masahiro, Hirose, Hiroshi, Ebinuma, Hirotoshi, Irie, Junichiro, Ojiro, Keisuke, Oikawa, Yoichi, Saito, Hidetsugu, Itoh, Hiroshi, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020466/ http://dx.doi.org/10.1155/2014/302602

Ejemplares similares

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
por: Hirata, Takumi, et al.
Publicado: (2013)

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
por: Vitale, Cristiana, et al.
Publicado: (2005)

Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model
por: Graus-Nunes, Francielle, et al.
Publicado: (2019)

Effects of telmisartan and losartan treatments on bone turnover markers in patients with newly diagnosed stage I hypertension
por: Aydoğan, Berna İ, et al.
Publicado: (2019)

Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients
por: Yoo, Yung-Geun, et al.
Publicado: (2023)

Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open-label Study
por: Kalikar, Mrunalini, et al.
Publicado: (2017)

Telmisartan, when compared to losartan, shows additional beneficial effects to pancreatic islet structure and function in diet-induced obese mice
por: Graus-Nunes, Francielle, et al.
Publicado: (2015)

Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis
por: Kumari, Kusum, et al.
Publicado: (2022)

Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19
por: Rothlin, Rodolfo Pedro, et al.
Publicado: (2023)

A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease
por: Vos, Miriam B., et al.
Publicado: (2018)

Telmisartan and cardioprotection
por: Akhrass, Philippe R, et al.
Publicado: (2011)

Drug-Induced Liver Injury Due To Losartan
por: Diogo, Joana, et al.
Publicado: (2021)

Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs
por: Golder, Matthew R., et al.
Publicado: (2018)

Losartan-induced Pancreatitis
por: Anwar, Shamsuddin M, et al.
Publicado: (2019)

Efficient and improved synthesis of Telmisartan
por: Kumar, A Sanjeev, et al.
Publicado: (2010)

Telmisartan induced urticarial vasculitis
por: Mahajan, Vikram K., et al.
Publicado: (2015)

Telmisartan/hydrochlorothiazide-induced hepatotoxicity
por: Lorena, Marco, et al.
Publicado: (2015)

Telmisartan aggravates pustular psoriasis
por: Keerthi, Subramaniam, et al.
Publicado: (2015)

Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study
por: Higaki, Jitsuo, et al.
Publicado: (2016)

The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review
por: Borém, Luciana M. A., et al.
Publicado: (2018)

Prediction of Effect of Pegylated Interferon Alpha-2b plus Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Infection
por: Takayama, Tetsuro, et al.
Publicado: (2011)

Is the combination of enalapril and losartan irrational?
por: Parmar, D.M., et al.
Publicado: (2008)

Impact of telmisartan in modifying vascular risk
por: Baguet, Jean-Philippe, et al.
Publicado: (2010)

Renoprotective effects of telmisartan after unilateral renal ablation in rats
por: Matsuo, Tomohiro, et al.
Publicado: (2013)

A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial
por: Lake, Jordan E., et al.
Publicado: (2013)

Telmisartan Self-Nanoemulsifying Drug Delivery System, Compared With Standard Telmisartan, More Effectively Improves Hepatic Fibrosis in Rats
por: Murad, Hussam, et al.
Publicado: (2020)

Renovascular and renoprotective properties of telmisartan: clinical utility
por: Ladino, Marco, et al.
Publicado: (2010)

RP-HPLC Estimation of Ramipril and Telmisartan in Tablets
por: Kurade, V. P., et al.
Publicado: (2009)

Polymorphism of ORM1 Is Associated with the Pharmacokinetics of Telmisartan
por: Chen, Wang-Qing, et al.
Publicado: (2013)

Telmisartan Treatment of Refractory Proteinuria in a Dog
por: Bugbee, A.C., et al.
Publicado: (2014)

Efficacy and Safety of Azilsartan and Telmisartan in Hypertensive Patients
por: Kumar, Alok, et al.
Publicado: (2021)

Telmisartan Attenuates Kanamycin-Induced Ototoxicity in Rats
por: Lee, Chang Ho, et al.
Publicado: (2021)

Comparison of the GPVI inhibitors losartan and honokiol
por: Onselaer, Marie-Blanche, et al.
Publicado: (2019)

Effect of a fixed-dose combination of Telmisartan/S-amlodipine on circadian blood pressure compared with Telmisartan monotherapy: TENUVA-BP study
por: Kim, Bong-Joon, et al.
Publicado: (2022)

Efficacy and safety of single-pill amlodipine/losartan versus losartan in patients with inadequately controlled hypertension after losartan treatment: a multicenter, double-blind, randomized phase III clinical trial
por: Zhang, Shuyang, et al.
Publicado: (2023)

Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [ (11)C]Telmisartan
por: van der Hoek, Sjoukje, et al.
Publicado: (2022)

Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
por: Ripley, Elizabeth, et al.
Publicado: (2010)

Comparison of the relative importance of vascular and plasma drug concentrations to the hypotensive effect of telmisartan in rats
por: Takai, Shinji, et al.
Publicado: (2016)

Changes in Glycated Human Serum Albumin Binding Affinity for Losartan in the Presence of Fatty Acids In Vitro Spectroscopic Analysis
por: Szkudlarek, Agnieszka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7jlfpouot3fbk9sscvd6nftj8t